CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Recent analyst optimism and upcoming reimbursement catalysts (NTAP effective Oct 1) provide a positive outlook, though technical indicators suggest caution following recent insider selling.
The Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case for the Ceribell Delirium Monitor System. This reimbursement, effective October 1, 2026, is expected to drive adoption and revenue growth for the company's delirium monitoring solution.
StockTitanFollowing investor meetings with management, BTIG reiterated a Buy rating and $30 price target for CBLL. The firm highlighted confidence in the company's growth drivers, including the Veterans Affairs expansion and the upcoming delirium launch, as well as a strong gross margin profile.
Investing.comMultiple executives, including the CEO and CFO, reported selling shares of common stock in mid-September 2026. These transactions were executed pursuant to pre-arranged Rule 10b5-1 trading plans, which are typically used to sell shares systematically rather than based on non-public information.
StockTitan